Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Principia Biopharma Inc.
Headquarters: South San Francisco, CA, United States of America
Website: N/A
Year Founded: 2008
Status: Acquired
BioCentury | Apr 24, 2024
Product Development
Clinical report: Sanofi data advances pair of autoimmune disease mechanisms
Plus: Neurocrine hits in Phase II depression study and updates from Cerevel, Sage, Ventus, Lilly and AbbVie
BioCentury | Sep 20, 2023
Data Byte
Immunology companies acquired by pharmas in 2020-23
At least 13 immunology-focused biotechs have been acquired for ≥$1B since start of 2020, with three of the deals announced this year
BioCentury | Apr 27, 2023
Product Development
April 27 Quick Takes: AbbVie exits CF based on triplet’s readout
Plus: AZ cuts late-stage GLP-1, Wilson’s disease programs and updates from Sanofi, 4D Molecular, Generate
BioCentury | Apr 5, 2023
Finance
With second post-GSK fund, SR One navigates changes along independent path
Nearly three years after firm’s separation, former parent still a presence, while new hires and sector headwinds drive investment decisions
BioCentury | Feb 4, 2023
Product Development
Feb. 3 Quick Takes: Sanofi terminates myasthenia gravis Btk program
Plus: Keytruda meets in first-line endometrial cancer and Roivant raises $200M in a follow on
BioCentury | Oct 14, 2022
Emerging Company Profile
Matchpoint: a toolkit to create covalent therapies for immunology
Chemoproteomics, machine-learning start-up has $100M from investors including Atlas, Access Biotechnology and Sanofi Ventures
BioCentury | Jun 30, 2022
Product Development
Sanofi sheds billions after program from Principia deal hits clinical snag
Shares dip after FDA places partial clinical hold on five Phase III trials of brain-penetrant Btk inhibitor for MS, myasthenia gravis
BioCentury | May 25, 2022
Emerging Company Profile
Terremoto carves out new chemical space with lysine-based covalency platform
Backed by Third Rock and OrbiMed, start-up aims to balance portfolio with best-in-class treatments and therapies against previously undruggable targets
BioCentury | Apr 8, 2022
Management Tracks
Ancestry’s Georgiadis joins Flagship as CEO-partner
Plus Melton rejoining Sanna at Vertex and updates from CARsgen, Third Harmonic and more
BioCentury | Jan 7, 2022
Data Byte
Well-funded Alumis advancing TYK2 entrant in crowded field
Psoriasis pipeline contains at least 11 TYK2 inhibitors
Items per page:
1 - 10 of 59